Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afuresertib Combined With Paclitaxel in Pre-treated HER2-negative Advanced Gastric Cancer
NCT02240212Phase 1Completed
- Sponsor
- Novartis
- Start
- Oct 2014
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of afuresertib in gastric cancer (GC) (3 arms), sponsored by Novartis. Primary endpoints: Number of subjects with any serious adverse event (SAE), non-serious adverse event (AE), Assessment of changes in clinical laboratory tests and 4 more. Started Oct 2014; status: completed.
02
Drugs
afuresertib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT02240212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02240212.